newdrugapprovals.org
Daiichi Sankyo enrolls first patient in Nimotuzumab Phase 3 clinical trials
Nimotuzumab 25 April 2013 Daiichi Sankyo Company, Limited announced today that the first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab (DE-766), a recombinant huma…